Related Experiment Videos
[Brain metastases of malignant melanomas]
C Boaziz1, J L Breau, J F Morere
1Service d'oncologie médicale, hôpital Avicenne, Bobigny, France.
Abstract:
Cerebral metastases of malignant melanoma are correlated with a very poor prognosis. Surgery of an isolated metastase can lead to a long survival but the brain lesions are frequently numerous and associated with an extracerebral diffusion. Dacarbazine (DTIC) gives a mean response rate of 21% on visceral localisations but doesn't cross the blood brain barrier (BBB). Neither do the biological response modifiers like Interleukin 2 (Il2) that leads to 25% response rate in disseminated melanoma. Nitrosoureas like carmustine (BCNU) and semustine (CCNU) have been investigated in different non randomised studies and the clinical results didn't illustrate their theorical ability to cross the BBB. Radiotherapy is also used as a palliative therapy with 7 to 16 weeks survival. Fotemustine (muphoran), a new amino acid linked nitrosourea, can give a response rate up to 28.2% in patients with cerebral metastases and the increased survival of responding patients is significant. The availability of this new drug may suggest associations with surgery and radiotherapy in the future to improve the survival of such patients.
Insights
Malignant melanoma brain metastases have a poor prognosis. Fotemustine, a novel nitrosourea, shows promise with a 28.2% response rate, potentially improving survival for these patients.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Context:
- Cerebral metastases from malignant melanoma are associated with a poor prognosis.
- Current treatments like surgery, chemotherapy (Dacarbazine), and biological response modifiers (Interleukin 2) have limitations in treating brain metastases.
- Existing nitrosoureas (BCNU, CCNU) show limited efficacy due to poor blood-brain barrier penetration.
Purpose:
- To evaluate the efficacy of fotemustine (muphoran), a new nitrosourea derivative, in patients with cerebral melanoma metastases.
- To assess the response rate and survival impact of fotemustine in this patient population.
Summary:
- Fotemustine, an amino acid-linked nitrosourea, demonstrated a response rate of up to 28.2% in patients with cerebral melanoma metastases.
- Unlike other agents, fotemustine can cross the blood-brain barrier, offering a therapeutic advantage.
- Responding patients showed a significant increase in survival.
Impact:
- Fotemustine represents a promising therapeutic option for malignant melanoma with brain metastases.
- Its availability may lead to combination therapies with surgery and radiotherapy to enhance patient survival.
- Further research into fotemustine's role in multimodal treatment strategies is warranted.